Companies › National Vaccine and Serum Institute, China
2 active drug programs in 2 registered trials: 2 Phase 3; Infectious disease; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha) Recombinant HPV vaccine covering 11 HPV types | HPV | Phase 3 | HPV InfectioN | Jun 2028 |
| Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) Recombinant human papillomavirus vaccine (HPV types 6, 11, 16, 18) | HPV6, HPV11, HPV16, HPV18 | Phase 3 | Human Papillomavirus (HPV) Infection | Jul 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05262010 | 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha) | Phase 3 | HPV InfectioN | Infectious disease | Jun 2028 |
| NCT06632912 | Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | Phase 3 | Human Papillomavirus (HPV) Infection | Infectious disease | Jul 2032 |
Merck & Co. (MSD) Beijing Health Guard Biotechnology Shanghai Bovax Biotechnology
Beijing Health Guard Biotechnology Shanghai Bovax Biotechnology ARJ Medical NPO Petrovax Xiamen Innovax Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.